Advertisement

Pharmaceutisch Weekblad

, Volume 2, Issue 1, pp 1605–1608 | Cite as

Nieuwe geneesmiddelen bij de ziekte van Parkinson

  • A. C. Van Loenen
Wetenschappelijke Mededelingen

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatuur

  1. Agid, Y., e.a. (1979a)Lancet I, 570–572.Google Scholar
  2. Agid, Y., e.a. (1979b)Biomedicine 30, 67–71.Google Scholar
  3. Bédard, P., J. D. Parkes enC. D. Marsden (1978)Brit. Med. J. 1, 954.Google Scholar
  4. Birkmeyer, w. (1976) In:Advances in Parkinsonism (Birkmeyer, W., enO. Hornykiewicz, Eds.) Basel, 407.Google Scholar
  5. Calne, D. B., e.a. (1974)Lancet II, 1355.Google Scholar
  6. Calne, D. B. (1978)Lancet I, 735.Google Scholar
  7. Editorial (1978)Lancet I, 754–755.Google Scholar
  8. Editorial (1980)Lancet I, 293.Google Scholar
  9. Gerstenbrand, F., W. Poewe enJ. Rainer (1978)Pharmakotherapie I, 190–194.Google Scholar
  10. Goldstein, M., e.a. (1978)Pharmacology 16 (suppl. I), 143–147.Google Scholar
  11. Hornykiewicz, O. (1978)Pharmokotherapie I, 176–181.Google Scholar
  12. Kastin, A. J., enA. Barbeau (1972)Canad. Med. Assoc. J. 107, 1079.Google Scholar
  13. Lieberman. A., e.a. (1979)Lancet II, 1129–1130.Google Scholar
  14. Lucking, C. H. (1978)Pharmakotherapie I, 182–189.Google Scholar
  15. Manaka, S., e.a. (1974)Experientia 30, 179.Google Scholar
  16. Papavasilou, P. S., e.a. (1978)Arch. Neurol. 35, 787–791.Google Scholar
  17. Parkes, J. D. (1979)Drugs 17, 365–382.Google Scholar
  18. Schachter, M., e.a. (1979)Lancet II, 1129.Google Scholar
  19. Schuster, S., e.a. (1973)Lancet I, 463.Google Scholar

Copyright information

© Bohn, Scheltema & Holkema 1980

Authors and Affiliations

  • A. C. Van Loenen
    • 1
  1. 1.St. Prot. Chr. StreekziekenhuisBennekom

Personalised recommendations